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Based on the idea that more human resources are needed in
the drug/vaccine/diagnostics research and development field
in the developing countries where new products are re-
quired to improve their unique health situation different
from developed countries, a new educational programme
has been launched in Japan. Here, I would like to show
briefly its philosophy, strategy and contents. This pro-
gramme has not been completed, however, we have started
a core diploma course that is consisted of seven modules
that cover all the steps to develop a new product from a very
basic discovery. This course has been made possible by a
synergistic cooperation between several good persons from
various institutions. Their names and institutions are as fol-
lows, Win Gutterrage, Janis Lazdins, Juntra Karbwang
(World Health Organisation, Switzerland), JinHong Hu
(Second Military Medical University, China), Kesara Na-
Bangchang (Thammasat University, Thailand), Chitr Sitthi-
amorn (Chulalongkorn University, Thailand), Kiichiro Tsu-
tani (University of Tokyo, Japan), Ivan Valez (University of
Antioquia, Colombia), and Kenji Hirayama (Nagasaki Uni-
versity, Japan).
I would like to acknowledge Kazuhiko Mori, Center for
Product Evaluation, Pharmaceutical and Medical Devices,
PMDA, Japan, Kihito Takahashi, Japanese Association of
Pharmaceutical Medicine (JAPHMED), Masaru Iwasaki,
GlaxoSmithKline, Tokyo, Japan, Masakatsu Shibasaki,
(The University of Tokyo, and The Pharmaceutical Society
of Japan, PSJ), Hiroshi Saitoh (President, Nagasaki Univer-




The development of new drugs, vaccines and diagnostics is
complex, requiring many different skills. Each individual
involved in a part of product R&D must be aware of the
process overall and be able to relate their activities to it and
to the needs of the other participating scientists and clini-
cians. Research scientists seek the discovery and confirma-
tion of new knowledge by initiating or creating a hypothesis
and then transforming it first into a theory and later into a
new discovery. Product developers turn such discoveries
into full-grown products which address public health needs
through a long and quite different processes. Generally, re-
search and development are two different disciplines. Peo-
ple working in these two areas do not think alike; they have
different cultures. Often they work in isolation from each
other, so they do not understand each other well. However,
both disciplines are essential for the development of new
drugs, vaccines and diagnostics. Furthermore, discovery of
new knowledge is meaningless if it is not translated into
new products that meet the needs of the public health.
Currently, there are only few courses in the north that give a
good overview of the entire drug discovery and develop-
ment process such as post-graduate courses at University of
Cardiff, ECPM at University of Basel, University of Lyon
and may be a few others. In majority of countries around
the world, most of the topics related to product R&D are
scattered throughout the various university curricula, in-
cluding basic science, organic chemistry, immunology,
pharmacy, pharmacology, vaccinology and clinical pharma-
cology. However, everyone involved in research or develop-
ment must know their responsibilities and able to relate
their tasks to all the others which make up the process of
product R&D. The objective of the proposed course is to
pull together the various components needed for product R
&D into a dedicated MSc-PhD course. Discussions between
different universities who are interested in this project have
taken place on several occasions. Recently, six universities
in four countries (Japan, Thailand, China and Colombia)
have started working together to draft the content of the cur-
riculum.
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The curriculum is designed to provide basic knowledge of
the product R&D process. It aims to demonstrate that new
product discovery and the various development activities
such as chemistry, toxicology, clinical investigations and
regulatory practices are related as a continuous process, and
that one discipline cannot carry out the whole process on its
own.
Format of the course:
This is a joint project involving a number of universities in
different countries. During the first five weeks, all students
will take a core course on product R&D aimed at giving
them an overview of the process. It will be held on a rota-
tional basis in one of the participating universities. During
the next ten weeks, students will select for in-depth explora-
tion an area of their special interest, for example drug dis-
covery, toxicology or clinical, and for this period will work
in an institution that offers that specific area.
For the last 8 months, students will be attached to a specific
institution, pharmaceutical company or biotech to work on a
particular project.
The first four months of the course will be mainly lectures
and case studies. The remaining 8 months will be mainly
practical, including laboratory studies or clinical practice.
The course is modular to allow those who already work in
the area of product R&D to attend the appropriate parts of
the course. This would provide such personnel with the op-
portunity of reviewing and discussing the special problems
they encountered in their routine, real world work.
At the end of five weeks, students will be awarded a di-
ploma in product research and development from Nagasaki
University.
At the end of the first year, the successful students may re-
ceive a MSc. (subject to university requirement). Progres-
sion to PhD will depend on the evaluation of their first year
performance. Those chosen as PhD candidates will do their
thesis in the area of interest in one of the companies with on
-going activities. Each student will receive their degree
from the university that they registered for the course.
Contents of the core diploma course
This part of the course will begin with a general overview
of product R&D (drugs, vaccines and diagnostics), continue
with a series of lectures on discovery research, transitioning
between research and development, CMC (chemical, manu-
facturing and control) requirements, toxicology require-
ments from development to product license, pharmaceutical
and analytical development, pharmacokinetics and meta-
bolic studies, clinical studies - phase I-IV trial design and
protocols - project planning and management, handling of
safety data in development, regulatory requirements, post
regulatory clinical studies, patents issues and other aspects
of product development i.e. international standards of good
practice, ethics in clinical research, DSMB (Data and safety
Monitoring Boards), commercial and marketing activities,
and public health implementation.
Contents of the course during the next ten weeks:
The students will focus on the area of their interest. They
will attend seminars and lectures in specific area such as
discovery, CMC, toxicology, vaccinology, pharmacology,
clinical development and regulatory requirements. For this,
the student can choose to attend at their registered univer-
sity (if such course is running during the period) or at an-
other affiliated institution.
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The program of core course in product R&D (Syllabus)
Module 1: Course Orientation
This module provides an over view of the need for a spe-
cific drug or vaccine for a disease or condition. The chal-
lenge for pharmaceutical research is to analyze a disease or
condition to determine its effect on the body. This analysis
leads to discovery of drug, vaccine or diagnostic which
could then turn into a product. Resource requirements of
current development paradigm and the time taken to de-
velop a new product will be discussed.
The following topics will be covered:
Key medical and public health issues, and the need
for new products
Discovery research and product development and
the different approaches required for each of them
Resource implication for product development
Stakeholders in Product Research and Development
Major players






Module 2: Drug Development
Discovery Research:
A comprehensive review of various approaches for new
drug discovery from early history of mankind to contempo-
rary techniques such as rational drug design, medicinal
chemistry, in silico technology, genomics, proteomics, and
pharmacogenomics will be covered. Examples of therapeu-
tic areas derived from these approaches will be provided in-
cluding lessons learned, pitfalls, and evolution towards a
newer and more efficient approach. The importance of hav-
ing the patents protected in the early stage as well as the
strategy to publish (or not publish) the novel findings will
be discussed.
The following topics will be covered:
・Historical





Chemical Development: Chemistry, manufacturing
and control (CMC):
The required standards for composition, manufacture proc-
ess, and controls information of the drug substance and the
drug product that can ensure proper identification, quality,
purity and strength of the investigating product will be de-
scribed.
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Following topics will be covered:
・Synthesis of active pharmaceutical ingredient
・Formulation
・Methods for determination of concentrations in
various media by means of spectrometric methods,
electromechanical methods, HPLC, gas chroma-
tography and biological methods
・Stability for drug substance and drug product
・Development of specification
・Quality assurance/quality control
・Regulatory (with an example of a drug CMC re-
quirement)
・Naming the New Chemical Entity
Preclinical development
The purpose of the Preclinical studies is to evaluate the
pharmacological activity and toxicity of a drug candidate.
The contents describe principles of pharmacology and toxi-
cology, including the types of pharmacological and toxico-
logical testing both in vitro and in vivo (animal model) and
pharmacokinetics.
The following topics will be covered:
・Pharmacological development
・Principles & knowledge of methodology
・Pharmacological Tests:
in vitro




・Toxicological Tests: in vitro & in vivo: acute,
subacute, chronic, special organ toxicology, re-
production toxicology, teratogenicity, mutagenic-
ity, carcinogenicity studies
・Scheduling of toxicological studies in the de-
velopment plan, the registration requirements, hu-
man & animal pharmacology, the proposed clini-
cal application and the forms of administration.
・Continuous monitoring of the correlation be-
tween new toxicological findings and the un-




Pharmacokinetic Data Analysis & Phar-
macokinetic Parameters
・Transferability of the pharmacokinetic findings
in animals to humans
・Investigating toxicological problems - practices
and pitfalls
・Evaluation of viability (risk and benefit) for fur-
ther development (case study)
Clinical development
The overview of clinical development will be presented, in-
cluding the assessment of pre-clinical information package
and clinical development plan. The important of human
pharmacokinetics and pharmacodynamics in drug develop-
ment will be discussed. Description of different clinical trial
phases will be presented with examples. Different trial de-
signs suitable for each type of studies will be illustrated,
sample size calculation, statistical analysis plan and issues
encountered during clinical development will be empha-
sized. An example of statistical analysis report will be dem-
onstrated. Clinical data management methodology will be
introduced. The regulatory requirements for clinical devel-
opment and process of regulatory submission will be dis-
cussed.
Following topics will be covered:
・Overview
・Assessment of pre-clinical information
・Clinical development plan
・Application of pharmacokinetics and pharma-
codynamics in drug development
・Dose selection and regimen
・Clinical trials
・The various investigational phases of clinical
research (Phases I-IV)
Human pharmacokinetics and pharma-
cogenetics
・Definition and significance of pharma-
cokinetic parameters ( absorption ,
bioavailability, binding to proteins, distri-
bution, clearance, elimination half life,
AUC)
・Special human-pharmacokinetic studies e.
g. bioavailability studies of multiple-dose,





Safety monitoring and reporting in clinical
trials
・Basic principles and evaluation of investiga-
tional results
(Phase-I and early Phase-II), with a view to fur-
ther development
・Basic principles for decisions regarding further




・possible study designs taking into account ethi-
cal aspects, indication, controls, patient popula-
tion, location of the trial centers
・Trial design (parallel group design, cross over
design, factorial design)







・biostatistics in the planning phase (estimate of
number of cases, randomization, statistical mod-
els, definition of end-points, planning of the sub-
sequent evaluation)
・Statistical analysis plan
・Analysis sets: full analysis set, per protocol set,
missing values and outliers
・Data transformation
・Method of statistical analysis (estimation, con-
fidence intervals, hypothesis testing, evaluation of
safety and tolerability
・Statistical analysis report
・Introduction to Clinical Data Management
・Regulatory aspects of clinical development
Module 3: Vaccine Development
Rational: World eradication of small pox clearly showed
that vaccine is a powerful tool to control the disease. First
of all, we will discuss about the reasons why some vaccine
developments were successful whereas some were not.
Then we will discuss what types of vaccine or vaccine de-
velopment are ideal to control the major diseases such as in-
fectious diseases, cancer, autoimmune diseases etc.
Discovery Research - Vaccines
Vaccine effect is dependent on the acquired immunity that
directed for the elimination of non-self including micro-
organisms, parasites, and cancer cells induced by the immu-
nization of some appropriate antigens. What is the most ef-
fective acquired immunity against the disease? How do you
select good antigens for such an effective vaccine develop-
ment? And how do you make that antigen(s) more effec-
tive? We will see the most advanced knowledge and tech-
nology that will facilitate vaccine discovery research.
A historical review and overview of modern vaccine discov-
ery will be presented. Various methods for antigen screen-
ing such as bioinformatics, protein chemistry, recombinant
antigens, high-throughput, cell free recombinant system
will be discussed. The evaluation of candidate antigens and
selection of candidates for development will be described.
Alternatives to using antigens will be presented. Examples
of antigens derived from these approaches will be provided
including lessons learnt, pitfalls, and evolution towards a
newer and more efficient approach. Different adjuvant will
be explored and discussed. The importance of having the
patents protected in the early stage as well as the strategy to
publish the novel findings will be discussed.
・Historical
・Overview of modern vaccine discovery
・Understanding the basic immunology of the
disease:
Acquired immunity, Protective immunity, anti-
gen, immunogenic
・Biological Targets and Vaccine Candidates
identification
・Infectious disease, Cancer therapy, Autoim-
mune,
・Screening for antigens
・Bioinformatics, Protein chemistry, recombi-
nant antigens, high-throughput method includ-
ing cell free recombinant system
・Evaluating antigens
・In vitro and in vivo tests including animal
model. Restriction for using animal model, ge-
netically engineered animals
・Adjuvant
・Type of the immune response provoked, new
type of adjuvant, recombinant cytokine as adju-
vant
・Alternatives to antigens
・DNA vaccine, Live or attenuated pathogen
・Selection of development candidate and back-ups
・Efficacy, toxicity, route if immunization,
price, stability, cold chain,
・Patents and publications
Antigen development
After or during identification of vaccine antigens, it will be
necessary to prepare appropriate amount and quality of anti-
gens for further study. Process of scale-up, manufacture and
control of the antigen will be demonstrated. Formulation of
the vaccine antigen according to the required standard will
be discussed.
・Scale-up, manufacture and control:
・Types of large scale production of antigen,
GLP and GMP
・Synthesis of antigen
・Peptide, recombinant protein, DNA vaccine,




・Mixture type or recombinant type
・Formulation
・Soluble or suspension, Route, frequency, in-
terval, number of dose, with or without adju-
vant, mucosal immunization (aerosol, oral, na-




Preclinical Safety and immunogenicity assessment for vac-
cine development is performed by using animal model.
There are two major check points, one is injection sites and
the other systemic effect such as hypersensitivity and auto-
immunity. Overview of the preclinical research will be
demonstrated by using several typical experiences for vac-
cine development. Methods for the safety assessment and
immunogenicity will be demonstrated. There will be a spe-
cial session to demonstrate the classical and novel concept
of animal model.
・Safety assessment
Toxicity test for animal: regional complications,
systemic toxicity such as fever, anaphylactic
shock,
・Immunogenicity assessment
・Animal model used in pre-clinical studies
・The use of humanized animal model
Clinical Development
Clinical development of vaccine is somehow different from
that of drug especially in the evaluation process and ethical
aspects. The participants in vaccine trial are usually healthy
volunteers and the sample size is normally greater than drug
trial. It also takes longer duration to demonstrate the effi-
cacy e.g. it needs a naturally infection to demonstrate the ef-
fect as challenging infection is not ethically acceptable. Ad-
ministration of vaccine requires more complex procedures
than drug trials, for example it requires cold chain, injection
instruments, health workers, etc.
The assessment of pre-clinical information to proceed to
human will be emphasized. In the Clinical trial section, the
various investigational phases of clinical research (Phases I-
IV) will be demonstrated. Basic principles and evaluation of
investigation, development project, Study design, Statistical
considerations, Data transformation Clinical Data Manage-
ment, regulatory
・Overview
・Assessment of pre-clinical information
・Clinical development plan
・Application of immunogenicity for vaccine
development
・Dose selection and regimen
・Clinical trial
・The various investigational phases of clinical
research (Phases I-IV)




Safety monitoring and reporting in
clinical trials
・Basic principles and evaluation of investiga-
tional results
(Phase-I and early Phase-II), with a view to
further development
・Basic principles for decisions regarding fur-
ther development or discontinuation of a devel-
opment project
・Study design
・possible study designs taking into account
ethical aspects, indication, controls, population,
location of the trial centers
・Trial design (parallel group design, longitu-
dinal design, factorial design, group sequential
designs






・biostatistics in the planning phase (estimate
of number of cases, randomization, statistical
models, definition of end-points, planning of
the subsequent evaluation)
・Statistical analysis plan
・Analysis sets: full analysis set, per protocol
set, missing values and outliers
・Data transformation
・Method of statistical analysis (estimation,
confidence intervals, hypothesis testing, evalu-
ation of safety and tolerability
・Statistical analysis report
・Introduction to Clinical Data Management
・Regulatory
Module 4: Diagnostic Development
Diagnostic tools in combination with therapeutic or preven-
tive medical care are important to develop for public health
purpose. Without good diagnostic method, it would be im-
possible to evaluate the disease burden in the community, to
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treat the patients and to protect the society against the dis-
ease.
Practical approach towards the development of really effec-
tive diagnostic tools for public health will be demonstrated
and discussed. In the overview, several excellent examples
will be shown. Discovery session will show three steps for
the discovery, Necessity assessment, technology selection,
prototype production. Evaluation of clinical applicability
such as Sensitivity and specificity will be discussed. De-
tailed protocol for the Clinical development will be demon-
strated.
・Overview
・Discovery and Development of diagnostic tools
・Necessity assessment, Principles and technol-
ogy selection, prototype production and assess-
ment.
・Identify preliminary diagnostic test
・Validation of clinical potential
・Identification of new targets using genomics
and protein and cellular studies
・Development of potential technology plat-
form
・Principles of diagnostic methods antibody
detection, antigen detection, biological parame-
ters including DNA, RNA, enzymes, proteins
・Define product specifications
・Feasibility assessment
・Scale-up, manufacture and control:
・Practical Application:
Development of kits, necessary equipments,
electricity, technician, budget
・Quality assurance/quality control: Evalu-
ation of the efficacy after application
・Clinical Development:
■ Validate prototype
■ Manufacture pilot lot
■ Initiate clinical trials




Module 5: Standards in Clinical Research and Develop-
ment
Regulations and guidelines vary from one country to an-
other. These regulations and guidelines dictate on how to
develop the product in each country. The product developer
must meet all the requirements and expectations of the
regulatory authorities as efficiently as possible. The module











・WHO Operational Guidelines for Ethics
Committees that Review Biomedical Research
・Principles of Research Ethics Autonomy, Benefi-
cence, Justice
・Research Methodologies and Ethical Issues
Biomedical Research including traditional
medicine
In Various Types of Health Research Genetic
Research & Stored Samples
・Ethics Committees
・Data and Safety Monitoring Boards
・Clinical Data Management
■ Data protection aspects
・Clinical study monitoring
・Audits and inspections
・US FDA Guidelines and regulation
・EMEA Guidelines and regulations
・Japan Guidelines and regulations
・China Guidelines and regulations
・Thailand Guidelines and regulations
・Colombia Guidelines and regulations
Module 6: Clinical Data Management
Project planning and management at every stage of devel-
opment will be described. Developmental objectives, cru-
cial milestones, concise detailed analysis of product and
roadmap to market will be demonstrated, including Patent
process. Regulatory strategies and strategies for dealing
with potential roadblocks and hurdles in the product devel-
opment process will be discussed. The plan will include a
lay out of an accurate and realistic budgets and timelines
throughout the project development. A practical workshop
on project planning and management will be included. Fol-
lowing topics will be covered:





■ CRF Design & Completion Guidelines





■ Database Programming and Standards
・Data
■ Data Entry
■ Data Processing: Validation (Edit Check
Specification)





■ Safety Data Management and Reporting
Module 7: Activities after Registration
Objective:
a. to identify stakeholders to be involved in post regula-
tory activities, their functions and roles in bringing the
products to solve the intended public health problems.
b. describe the policy instruments to bring the products to
the intended beneficiaries.
c. develop strategies for public and private partnership to
encourage
- Research and development in areas of need and
- Advocate the public sector to allocate funds to allocate
funds to bring products to the intended beneficiaries.
d. develop evidence based actionable message, identify
resources requirement to scale up the products for use
in the health care system (diagnostic tests, vaccines
and drugs) as well as describe strategies to mobilize
these resources.
e. describe mechanisms and strategies for post marketing
product vigilance for product quality, post marketing
efficacy and side effects.
f. Identify the human resource capacity strengthening
needs and strategies to fulfil those needs such as
through best practice health services research using
“unqualified” personnel and training of the trainers.
Stakeholders to be involved in making product de-
velopment work for the intended beneficiaries
Stakeholders in health care systems are important in making
development products work for poor people and intended
beneficiaries. These include the policy makers, the system
managers, directors of facilities, the practitioners and the in-
tended beneficiaries. Each of these stakeholders has unique
responsibility, roles and functions. The roles and functions
have to be coordinated to make the system make the prod-
ucts work. The unique roles, functions and the tools to coor-
dinate the stakeholders to make the product work will be
described with specific examples for HIV/TB care and ad-
dressing poverty gender based inequalities and how to deal








Social factors to a large extent shape the success for failure
of bring innovative products to benefit the intended benefi-
ciaries. Policy instruments are needed to deal with the com-
plexity of social impediments to health and diseases. The
use of the policy instruments will need the right understand-
ing of diseases and their proximate and distant determinants.
The right understanding can give insight to: a) targeting the
products; b) development rules and regulation to procure
and provide the products to the intended beneficiaries; c) al-
location of resource to finance the purchase of the products
to target beneficiaries and d) development of services either
at the public or private sectors where appropriate. Specific
instruments to be discussed in details are:
・Public health need and vulnerable groups
・Targeting
・Rule regulation (financing, guidelines)
・Resources allocation
・Service planning: primary, secondary, tertiary
care
Public Private Partnership (3 hours)
The purpose of partnership between the public and private
sector is to promote the interface between product develop-
ment and their use in clinical and systems settings. Partner-
ship can have an effect of the overall priorities and suc-
cesses of product development. A good partnership will
strengthen the credibility of the relationship between the
public and private sector over the long term. There are sev-
eral possible reasons to develop a public and private part-
nership. The most important one should be the need to
achieve a task, which is not achievable if each of the part-
ners works independently. Typically, these activities help
control a ’neglected’ disease or condition in developing
countries such as through development or distribution of a
drug, diagnostics, vaccines, contraceptive and other prod-
ucts. In general, there are two types of partnership:
1) those that want to tackle a problem in a more efficient
way; and
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2) those that are created to tackle what is conceived as in-
tractable problems such as the development of a malaria
vaccine. These partnerships want to find new ways of tack-
ling the problems because the world does not yet know how
to do it. Since the cost of product development can be high,
economic consideration to promote an interface between
development/clinical use and approval, post marketing must
be in place. Both the “push” and “pull” mechanisms will be
described. The “push” mechanism guide the research and
development initiatives, while the “pull” mechanism ensure
that the public sector will guarantee allocation of funds to
purchase products for the intended beneficiaries once they
are available.
・Public-private partnership
・Function and structure of partnerships
・Good characteristic of partnerships
・Monitoring partnerships
・Examples of partnerships for product research
and development
Improving the quality use of new products in health
systems
Evidence for efficacy and safety of the products must be in-
terpreted for potential users of the products to enhance qual-
ity use for intended beneficiaries. The potential users in-
clude policy makers, practitioners, patients and public, in-
cluding the media. The interpretations have to be trans-
formed into evidence based actionable products relevant for
each of potential users. Other strategies such as the “triangle
that moves the mountain” and the “academic NGO” move-
ment of the University of Ottawa can be used to develop
strategies to link evidence based actionable message to po-
tential users.
・Diagnosis
- Characteristics of tests and resource needed to
implement the test in health system.
- Access to diagnostic services and case finding
for poverty and gender-based inequalities
- Balancing public protection and stigmatization
and denial (TD/HIV)
・Vaccine:
- Characteristics of Vaccine and resource needed
to implement the test in health system.
- Coverage and herd immunity
- Post vaccination exposure and risk activities
・DRUG.
- Indications, contraindications, use and resource
needed to implement the test in health system.
- Compliance of provider
- Compliance of subjects
- Measures to improve compliance
Post marketing product vigilance
New products, such as drugs, vaccines and diagnostic tests
have both benefits and side effects, some of which might
not be apparent until the products have been used over a
long period of time. Therefore, a system must be developed
to measure the benefits as well as risks. Benefits need to be
weighed against the occurrence of adverse events. A risk/
benefit analysis of the products must be evaluated using
standardized tools and procedures. The importance of guid-
ance for standardization of terminology, data collection,
verification and presentation of efficacy and adverse reac-
tion reports will be emphasized and discussed.
Possible topics include:
・The definition of pharmacovigilance.
・The scope, instruments/tools, and processes
needed for Pharmacovigilance of medicinal prod-
ucts for human use.
・Systems for standardization of pharmacovigilance
reporting and exchange of pharmacovigilance in-
formation and subsequent appropriate actions.
・Administrative and legislative information rele-
vant to medicinal products for human use.
・The mechanism for reviewing and updating legis-
lative and technical areas for general use.
Capacity for optimal delivery of new product:
Training and Health services research
It is important that countries have the capacity to identify,
innovate and adapt new products to its own need and con-
straints in order to address their unique burden of illnesses
including the burden of tropical diseases. At times, health
service research might be carried out to document the possi-
bility of using products via “unqualified personnel” through
training to ensure best practice (such as the use of nurses for
provide contraceptive services). Policy formulation, imple-
mentation and evaluation must be in place. Most developing
countries do not have capacity to formulate policy identify,
innovate and adapt new products to relevant to their prob-
lems. Vaccines against ROTA virus, which was not ap-
proved in the US due to rate intussusceptions might have be
very beneficial in developing countries in preventing burden
of illnesses from ROTA virus diarrhea over the incidence of
complications because the incidence of ROTA virus diar-
rhea is high. Likewise, capacities for the development of
treatment guidelines and their financing, and optimal facil-
ity planning for new products are needed to optimally dis-
tribute and use the new products for the intended beneficiar-
ies. Individual practitioners also need skills to search for the
best evidence about the use of products within the con-
straints of their health systems. Various models of interna-
tional collaboration for capacity strengthening are available
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such as the Thai Golden Jubilee grant. The topics to be con-
sidered and discussed include:
・Policy formulation, implementation and evalu-
ation
・Guidelines & Finance (insurance)
・Optimal facility planning and program manage-
ment.
・Evidence based search for best information for
practitioners, subjects
・Model for capacity strengthening through interna-
tional collaboration.
Agenda of the diploma course of 2006
Diploma Course on Research & Development of Products
to Meet Public Health Needs
Sponsored by Nagasaki University
in cooperation with Thammasat University, Chulalongkorn University,
China Second Military Medical University, Antioquia University
and The Graduate School of Pharmaceutical Sciences of The University of Tokyo
in collaboration with WHO and The Pharmaceutical Society of Japan (PSJ)
Nagasaki University, Japan
October 2－November 8, 2006
Tentative agenda
Module 1 Course Orientation
October 2, 2006 Monday
0900-0915 Welcome address
President, Prof Dr. Hiroshi Saitoh, Nagasaki
University, Japan
0915-0945 Objective of the course
Professor Dr. Kenji Hirayama, Director of
the course, Nagasaki University, Japan
0945-1000 Introductions of participants
1000-1030 Tea break
1030-1200 Key medical and public health issues, and
the need for new products
Dr. Janis Lazdins, WHO/TDR, Geneva
1200-1300 Lunch
1300-1400 Discovery research and product development
and the different approaches required for
each of them
Dr. Janis Lazdins, WHO/TDR, Geneva
1400-1500 Stakeholders in Product Research and Devel-
opment






Prof. Dr. Eiji Uchida, Showa University, To-
kyo, Japan
1500-1530 Tea break
1530-1600 Stakeholders in Product Research and Devel-
opment
1600-1630 Q&A
Module 2 Drug Development
Drug Discovery
October 3, 2006 Tuesday
0900-11.00 History and overview of modern drug dis-
covery
Mr Nobuhiro Noro, GSK, Japan
1100-1130 Tea Break
1130-1230 From drug target to drug lead
Mr Nobuhiro Noro, GSK, Japan
1230-1330 Lunch
1330-1430 Drug targets identification and validation in
malaria
TBA
1430-1530 Drug targets identification and validation in
TB
Assoc. Prof. Dr. Prasit Palithapolkarnpim,
BIOTEC, Thailand
1530-1600 Tea break
1600-1700 Drug targets identification and validation in
cardiovascular diseases
Dr.Kihito Takahashi, Japanese Association
of Pharmaceutical
１０８
Medicine (JAPHMED), Merck Banyu
Pharma, Japan
October 4, 2006 Wednesday
0900-1030 Overview of chemistry in drug discovery
Hit/lead generation and optimisation
Dr. Prof. Yoshimoto, Nagasaki University,
Nagasaki, Japan
1030-1100 Tea break
1100-1200 Drug discovery for Prion disease
Prof. Shigeru Katamine, Nagasaki Univer-
sity, Nagasaki, Japan
1200-1300 Lunch
1300-1430 Visit laboratory in Nagasaki University
(Prion Lab)
1430-1530 Drug discovery for TB
TBA
1530-1600 Tea break
1600-1700 Drug discovery for Trypanosomiasis
Prof. Dr. Kiyoshi Kita, University of Tokyo,
Japan
October 5, 2006 Thursday
0900-1000 Publications, IPR and patents in drug discov-
ery
Mr. Kenichi Osawa, Merck Banyu Pharma,
Japan
1000-1030 Tea break
1030-1130 Publications, IPR and patents in drug discov-
ery (Cont.)
Mr. Kenichi Osawa, Merck Banyu Pharma,
Japan
Chemical Manufacturing and Control (CMC)
October 6, 2006 Friday
0900-1000 Synthesis of active pharmaceutical ingredi-
ent
Prof Susumi Hatakeyama, Nagasaki Univer-
sity, Japan
10:00-10:30 Formulation
Prof Susumi Hatakeyama, Nagasaki Univer-
sity, Japan
1030-1100 Tea break
1100-1300 Methods for determination of concentrations
in various media by
means of spectrometric methods, HPLC, and
biological methods
Prof.Dr. Masaaki Kai, Nagasaki University,
Japan
1300-1400 Lunch
1400-1530 Stability for drug substance and drug prod-
uct
Prof.Dr. Hiroaki Nagaoka, Nagasaki Inter-
national University, Japan
1530-1600 Tea break
1600-1700 Development of specification
Prof.Dr. Hiroaki Nagaoka, Nagasaki Inter-
national University, Japan
October 7, 2006 Saturday
0900-1030 Quality assurance/quality control
Prof.Dr. Hiroaki Nagaoka, Nagasaki Inter-
national University, Japan
1030-1100 Tea break
1100-1200 Example: Antimalarial drug, dihydroartemis-
inin
Assoc. Prof. Supornchai, Mahidol University,
Thailand
1200-1300 Lunch
1300-1530 Regulatory (with an example of a drug CMC
requirement)
Prof.Dr. Hiroaki Nagaoka, Nagasaki Inter-
national University, Japan
1530-1600 Tea break
1600-1630 Naming the New Chemical Entity (NCE)




9 October 2006 Monday
0900-1100 Pharmacological data in new drug applica-
tion
Dr. Shunsuke Ono, University of Tokyo, Ja-
pan
1100-1130 Tea break
1130-1230 Methods in pharmacological R&D (1)
Dr. Hiroyuki Itoh, Astellas Pharma Inc, Ja-
pan
1230-1330 Lunch
1330-1430 Methods in pharmacological R&D (2)
Dr. Hiroyuki Itoh, Astellas Pharma Inc, Ja-
pan
1430-1500 Discussion
Drs. Shunsuke Ono and Hiroyuki Itou
1500-1530 Tea break
1530-1630 The cure oriented therapeutics for chronic
renal failure with gene therapy




10 October 2006 Tuesday
0900-1000 Principles of toxicology
Assoc. Prof.Dr. Wongwiwat Tassaneeyakul,
Kon Kaen University, Thailand
1000-1100 Toxicological tests: in vitro & in vivo: acute,
subacute, chronic, special organ toxicology,
reproduction toxicology, teratogenicity,
mutagenicity, carcinogenicity studies
Assoc. Prof.Dr. Wongwat Tassaneeyakul, Kon
Kaen University, Thailand
1100-1130 Tea break
1130-1300 Scheduling of toxicological studies in the
development plan, the registration require-
ments, human & animal pharmacology, the
proposed clinical application and the forms
of administration.
Dr. Soisanwan Satarug, University of
Queensland, Australia
1300-1400 Lunch
1400-1530 Continuous monitoring of the correlation be-
tween new toxicological findings and the un-
wanted events observed in humans up till
now.




11 October 2006 Wednesday
0900-1030 Principles of pharmacokinetics: ADME
processes
Assoc. Prof.Dr. Wongwat Tassaneeyakul, Kon
Kaen University, Thailand
1030-1100 Tea break
1100-1230 Pharmacokinetic data analysis & pharma-
cokinetic parameters
Assoc. Prof.Dr. Wongwat Tassaneeyakul, Kon
Kaen University, Thailand
1230-1330 Lunch break
13:30-1530 Transferability of the pharmacokinetic find-
ings in animals to humans investigating toxi-
cological problems - practices and pitfalls
Dr. Soisanwan Satarug, University of
Queensland, Australia
12 October 2006 Thursday
1000-1200 Visit animal facility for medical research
(Sato animal house)
1500-1630 Evaluation of viability (risk and benefit) for
further development
(Case study)
Dr Tadaaki Taniguchi, Japanese Association
of Pharmaceutical Medicine (JAPHMED),
Merck Banyu Pharma, Japan
Clinical Development
Clinical Trial
13 October 2006 Friday
0900-1100 Overview of clinical development
・Assessment of pre-clinical information
・Clinical development plan
・Application of pharmacokinetics and
pharmacodynamics in drug development
Dose selection and regimen
Dr. Tadaaki Taniguchi, Japanese Association
of Pharmaceutical Medicine (JAPHMED),
Merck Banyu Pharma, Japan n
1100-1130 Tea break
1130-1200 The various investigational phases of clinical
research (Phases I-IV)
Dr. Tadaaki Taniguchi, Japanese Association
of Pharmaceutical Medicine (JAPHMED),
Merck Banyu Pharma, Japan
1200-1300 Lunch
1300-1500 Human pharmacokinetics:
・Definition and significance of pharma-
cokinetic parameters ( absorption ,
bioavailability, binding to proteins, distri-
bution, clearance, elimination half life,
AUC)
・Special human-pharmacokinetic studies e.
g. bioavailability studies of multiple-dose,
interaction studies, pregnancy, liver dis-
ease etc.
Prof. Dr. Kesara Na Bangchang, Director,
Graduate Program in Biomedical Sciences,
Thammasat University, University, Thailand
1500-1530 Tea break
14 October 2006 Saturday
0900-1000 Therapeutic exploratory (with example)
Dr. Kenji Nonaka, Japanese Association of
Pharmaceutical Medicine (JAPHMED),
Merck Banyu Pharma, Japan
1000-1100 Therapeutic confirmatory (with example)
Dr. Kenji Nonaka, Japanese Association of
Pharmaceutical Medicine (JAPHMED),
Merck Banyu Pharma, Japan Tea break
1100-1130 Tea Break
1130-1230 Therapeutic use (with example)
Dr.Kimihiro Kasamo, Japanese Association
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of Pharmaceutical
Medicine (JAPHMED), Merck Banyu
Pharma, Japan
1230-1330 Lunch
1330-1500 Safety monitoring and reporting in clinical
trials
・Basic principles and evaluation of investi-
gational results
(Phase-I and early Phase-II), with a view
to further Development
・Basic principles for decisions regarding
further development or discontinuation of
a development project
Dr.Kimihiro Kasamo, Japanese Association
of Pharmaceutical Medicine (JAPHMED),
Merck Banyu Pharma, Japan Tea break
1500-1530 Tea Break
1530-1630 Pharmacogenomics
Dr. Shyh-Yuh Liou, Japan Section GlaxoS-
mithKline, Japan
Study design
16 October 2006 Monday
0900-1030 Study design
・Possible study designs taking into account
ethical aspects, indication, controls, pa-
tient population, location of the trial cen-
ters
・Trial design (parallel group design, cross
over design, factorial design, group se-
quential design)
・Design techniques to avoid bias (blinding,
randomization)
Prof. Dr. L. Jeeyaseelan, Christian Medical
University, Vellor, India
1030-1100 Tea break








・Biostatistics in the planning phase (esti-
mate of number of cases, randomization,
statistical models, definition of end-points,
planning of the subsequent evaluation)
・Statistical analysis plan
・Analysis sets: full analysis set, per proto-
col set, missing values and outliers
Prof. Dr. L. Jeeyaseelan, Christian Medical
University, Vellor, India
1500-1530 Tea break
1530-1700 Statistical considerations (Cont.)
・Data transformation
・Method of statistical analysis (estimation,
confidence intervals, hypothesis testing,
evaluation of safety and tolerability)
・Statistical analysis report
Prof. Dr. L. Jeeyaseelan, Christian Medical
University, Vellor, India
Regulatory Issues
17 October 2006 Tuesday
0900-1030 Regulatory aspects of clinical development
Dr. Kazuhiko Mori, Office of New Drug1,
Center for Product





・Gene therapy and stem cells
Dr. Kazuhiko Mori, Office of New Drug1,
Center for Product
Evaluation, Pharmaceutical and Medical
Devices, PMDA, Japan
1230-1330 Lunch
1530-1600 Example of Clinical Drug development in
Inida - Miltefosine trial
Prof. Dr. Juntra Karbwang, WHO/TDR,
Switzerland
Traditional Medicine
18 October 2006 Wednesday
0900-1030 Introduction to traditional Medicine: drug
discovery and development
Professor Dr. Kiichiro Tsutani, University of
Tokyo, Japan
1030-1100 Tea break
1100-1200 Guidance on herbal medicine
Prof. Dr. Juntra Karbwang, WHO/TDR,
Switzerland
1300-1500 Regulation for traditional medicine develop-
ment
Japan: Dr. Ichiro Arai, Manager, R&D Strat-
egy Dept. Tsumura & Co.
China: Dr. Luping Qin, China
Thailand: Dr. Vichai Chokevivat, Director,




1530-1700 Example: Herbal medicine to modern medi-
cine
Example: traditional medicine development
Dr. Luping Qin, China
Module 3: Vaccine Development
Vaccine Discovery
19 October 2006 Thursday
0900-0930 Historical of vaccine Discovery
Dr. Howard Engers, AHARI, Ethiopia
0930-1030 Overview of modern vaccine discovery
Dr. Howard Engers, AHARI, Ethiopia
1030-1100 Tea break
1100-1200 Screening for antigens




Prof Dr. Kenji Hirayama, Nagasaki Univer-
sity, Japan
1430-1500 Tea break
1500- Visiting Vaccine Discovery Laboratory Insti-
tute of Tropical Medicine, Nagasaki Univer-
sity
20 October 2006 Friday
0900-1030 Adjuvant -
Dr. Howard Engers, AHARI, Ethiopia
1030-1100 Tea break
1100-1200 Alternatives to antigens: DNA vaccine, Live
or attenuated pathogen
Dr. Howard Engers, AHARI, Ethiopia
1200-1330 Lunch
1330-1430 Selection of development candidate and back
-ups
Dr. Howard Engers, AHARI, Ethiopia
1430-1500 Tea break
1500-1630 Efficacy, toxicity, route if immunization,
price, stability, cold chain,
Dr. Howard Engers, AHARI, Ethiopia
21 October 2006 Saturday
0900-1030 Malaria vaccine discovery
Prof. Dr.Weiqing Pan, China
1030-1100 Tea break
1100-1200 Cholera vaccine discovery
Dr. Masahiko Ehara, Nagasaki University,
Japan
1200-1330 Lunch
1300-1400 West Nile Fever vaccine discovery
Prof. Dr.Kouichi Morita, Nagasaki Univer-
sity, Japan
1400-1500 Oral vaccine discovery




23 October 2006 Monday
0900-1030 Scale-up, manufacture and control:
Types of large scale production of antigen,
GLP and GMP
Dr. Horiuchi, GlaxoSmithKline, Tokyo, Ja-
pan
1030-1100 Tea break
1130-1230 Synthesis of antigen
Peptide, recombinant protein, DNA vaccine,
recombinant BCG or organism, live or at-
tenuated organism
Dr. Horiuchi, GlaxoSmithKline, Tokyo, Ja-
pan
1230-1330 Lunch
1330-1430 Synthesis of adjuvant
Mixture type or recombinant type




Soluble or suspension, Route, frequency, in-
terval, number of dose, with or without adju-
vant, mucosal immunization (aerosol, oral,
nasal, inhalation, food), instability
Dr. Horiuchi, GlaxoSmithKline, Tokyo, Ja-
pan
1530-1600 Quality assurance/quality control
Dr. Horiuchi, GlaxoSmithKline, Tokyo , Ja-
pan
Clinical Development
24 October 2006 Tuesday
0900-0930 The various investigational phases of clinical
research (Phases I-IV)
Dr. Horiuchi, GlaxoSmithKline, Tokyo, Ja-
pan
0930-1030 Basic principles and evaluation of investiga-
tional results
・Phase-I and early Phase-II, with a view to
further development




1100-1230 Basic principles for decisions regarding fur-
ther development or discontinuation of a de-
velopment project
Dr. Horiuchi, GlaxoSmithKline, Tokyo, Ja-
pan
Pre-Clinical Development
1330-1500 The use of humanized animal model
Dr. Kenji Hirayama, Nagasaki University,
Japan
25 October 2006 Wednesday
0900-1030 Animal model used in pre-clinical studies
Dr. Shigeyuki Kano, International Medical




1100-1130 Assessment of pre-clinical information
TBA
1130-1230 Clinical development plan
Professor Dr. Kenji Hirayama, Nagasaki
1230-1330 Lunch
1330-1430 Application of immunogenicity for vaccine
development
Dr. Shigeharu Ueda, The Research Founda-
tion for Microbial Diseases of Osaka Uni-
versity (BIKEN), Japan
1430-1500 Tea break
1500-1600 Dose selection and regimen
Dr. Shigeharu Ueda, The Research Founda-
tion for Microbial Diseases of Osaka Uni-
versity (BIKEN), Japan
Pre-Clinical Development
26 October 2006 Thursday
0900-1030 Safety assessment
Toxicity test for animal: regional complica-
tions, systemic toxicity such as fever, ana-
phylactic shock








Mr. Yoshino, Dr. Masaru Iwasaki, GlaxoS-
mithKline, Tokyo, Japan
1430-1500 Tea break
1500-1600 Example: Malaria Vaccine Clinical Trial De-
velopment
TBA
1600-1700 Example: TB Vaccine Clinical Trial
TBA
Module 4: Diagnostic Development
27 October, 2006 Friday
0900-1030 Discovery and development of diagnostic
tools:
Necessity assessment, Principles and tech-
nology selection
Dr.Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
1030-1100 Tea break
1100-1230 Prototype production and assessment
Dr.Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
1230-1400 Lunch
1400-1530 Scale-up, manufacture and control
Dr. Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
1530-1600 Tea break
1600-1730 Scale-up, manufacture and control (Cont.)
28 October, 2006 Saturday
900-1030 Development of kits
Dr. Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
1030-1100 Tea break
1100-1230 Quality assurance/quality control: evaluation
of efficacy after application
Dr. Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
1230-1400 Lunch
1400-1530 Clinical development: validate prototype,
manufacture pilot lot, and initiate clinical
trial
Dr. Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
1530-1600 Tea break
1600-1730 Clinical development: Supply chain logistics
and production, Statistical consideration,
regulatory issues
Dr. Masato Sasaki, Roche Diagnostics KK,
Tokyo, Japan
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Module 5: Standards in Clinical Research and Develop-
ment
Ethics in research and Ethics Committee
30 October, 2006 Monday
0900-1000 Ethics Codes and Guidelines
Prof. Dr. Cristina Torres, FERCAP, Thailand
1000-1100 Principles of Research Ethics




1400-1500 Research methodology and ethical issues (1)
Traditional medicine
Dr. Vichai Chokevivat, Director, Department
of Alternative Medicine, MOH Thailand
1500-1600 Research methodology and ethical issues (2)
Genetic study




31 October, 2006 Tuesday
0900-1030 Ethics Committee
Prof. Dr. Cristina Torres, FERCAP, Thailand
1030-1100 Tea break
1100-1230 Ethics committee Cont.
Prof. Dr. Cristina Torres, FERCAP, Thailand
1230-1400 Lunch
1400-1500 Data and Safety Monitoring Board (DSMB)
Prof. Dr. Juntra Karbwang, WHO/TDR,
Switzerland
1500-1630 Case study
1630-1730 Monitoring and auditing Ethics Committee
Prof. Dr. Cristina Torres, FERCAP, Thailand
1 November, 2006 Wednesday
Quality Standards
0900-09.30 Concept of Good Clinical Practice
Dr. Johansen, Allan, Roche Products Pty
limited, Australia
09.30-11.30 Responsibilities
Sponsor (Dr. Allan Johansen)
Investigators (Prof. Kenji Hirayama)
IRB (Prof. Cristina Torres)
Monitors (Prof. Juntra Karbwang)
DSMB (Dr. Allan Johansen)
11.30-12.00 Audit and Inspection
Dr. Johansen, Allan, Roche Products Pty
limited, Australia
1200-1300 Lunch
14:00-15:30 New Asymmetric Catalysis; Leading to the
synthesis of Tamiflu
Prof. Dr. Masakatsu Shibasaki, The Univer-
sity of Tokyo, Japan
2 November, 2006 Thursday
In the morning: Field Trip to Kaketsuken, Kumamoto
by Bus:
13:00-17:00 Good Manufacturing Practice (GMP)
Good Laboratory Practice (GLP)
Dr. Kyousuke Mizuno, Kaketsuken, Ku-
mamoto, Japan
Visit GMP lab and GLP lab and Plant for
vaccine production
3 November, 2006 Friday Holiday
Module 6: Clinical Data Management
6 November, 2006 Wednesday
0900-1000 Overview of clinical data management
Data management plan
Dr. Charcrin Na-Bangchang, TU-CDMC,
Thailand
1000-1030 Statistical Analysis Plan (SAP)
Data: primary & secondary data
Dr. Rui Wang, SMMC-CDMC, China
1030-1100 Tea break
1100-1230 Data capture , development of database
Prof. Dr. L. Jeeyaseelan, CMC-CDMC, India
1230-1330 Lunch
1330-1400 Data entry, data verification, data validation,
audit trail
Data clarification process
Data query and resolution
Prof. Dr. Kenji Hirayama, CMC-CDMC, Na-
gasaki University, Japan
Dr. Lawrence Yamua, AA-CDMC, Ethiopia
1400-1500 Data transform process
・Adverse Event Dictionary
・Drug Dictionary




Dr. Arunachalam Rajapopal, CMC-CDMC,
India
1700-1800 Quality Control & Assurance (QC & QA)
Standard Operating Procedures (SOPs)




7 November 2006 Tuesday
0900-1000 Stakeholders to be involved in making prod-
uct development work for the intended bene-
ficiaries
Prof. Dr. Chitr Sitthi-amorn, Chulalongkorn
University, Thailand
Prof. Dr. Pakdee Pothisiri, FDA, Thailand
Prof. Dr. Kazuko Kimura, Kanazawa Uni-
versity, Japan
Dr.Kihito Takahashi, Japanese Association
of Pharmaceutical
Medicine (JAPHMED), Merck Banyu
Pharma, Japan
1000-1100 Policy Instrument
Prof. Dr. Pakdee Pothisiri, FDA, Thailand
Prof. Dr. Chitr Sitthi-amorn, Chulalongkorn
University, Thailand
1100-1130 Tea break
1130-1230 Public private partnership
Prof. Dr. Chitr Sitthi-amorn, Chulalongkorn
University, Thailand
Prof. Dr. Pakdee Pothisiri, FDA, Thailand
Prof. Dr. Kazuko Kimura, Kanazawa Uni-
versity, Japan
1230-1330 Lunch
1330-1430 Public private partnership Cont.
1430-1500 Tea break
1500-1700 Pharmacoeconomics
Prof. Dr. Kiichiro Tsutani, University of To-
kyo, Japan
8 November 2006 Wednesday
0900-1700 Improving the quality of new products in
health systems: International network of re-
gional use of drugs
Prof. Dr. Chitr Sitthi-amorn (Chulalongkorn
University)
0900-1030 Post-marketing product vigilance
Dr. Janis Lazdins, TDR/WHO, Geneva, Swit-
zerland
Prof. Dr. Chitr Sitthi-amorn, Chulalongkorn
University, Thailand
Prof. Dr. Pakdee Pothisiri, FDA, Thailand
1100-1130 Tea break
1100-1200 Capacities for optimal delivery of new prod-
ucts: training and health service research
Prof. Dr. Chitr Sitthi-amorn, Chulalongkorn
University, Thailand
1200-1300 Lunch
1300-1430 Intellectual Property Rights Protection in
Developing Countries
Prof. Dr. Hiroko Yamane, Graduate Institute
for Policy Studies, Japan
1430-1500 Tea break
1500-1630 Product life cycle
Dr. Janis Lazdins, TDR/WHO, Geneva, Swit-
zerland
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